Aciex Therapeutics

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Aciex Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 8 completed upper quartile by trial count

Aciex Therapeutics: 8 sponsored US clinical trials, none currently recruiting.

Aciex Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 4 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Allergic Conjunctivitis, with 1 trials.

Upper-quartile sponsor footprint

Aciex Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 1

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

NCT02173249
COMPLETED Phase 3

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

NCT02132169
COMPLETED Phase 3

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
COMPLETED Phase 3

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01685242
COMPLETED Phase 3

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

NCT01551056
COMPLETED Phase 1

A Comparison of the Safety and Comfort of AC-170

NCT01495338
COMPLETED Phase 2

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

NCT01332188
COMPLETED Phase 2

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

NCT01134328

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 4

Therapeutic Areas

Allergic Conjunctivitis 1
Healthy 1

How the Aciex Therapeutics archive is shaped

8 indexed studies, none listed as recruiting (0% open); 8 completed (100%).

Phase mix: 4 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Allergic Conjunctivitis (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Aciex Therapeutics: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Aciex Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Aciex TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Aciex Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aciex Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aciex Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of Aciex Therapeutics or any single study.

  • None of Aciex Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Allergic Conjunctivitis is the condition Aciex Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Allergic Conjunctivitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Aciex Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.